Hayes RL, Lazaro L, Odaimi M, Scheff R, & Burton J.
Immunologic monitoring of peripheral blood changes in patients with
stage IV malignant melanoma or renal cell cancer treated with
sequential recombinant human GM-CSF (Leukine®) Interleukin-2 (IL-2,
Proleukin®) and PEG-Interferon α2b (PEG-IFN, PEG-Intron®) on a
Phase I/II clinical trial. Proc Amer Assoc Cancer Res, 2003
Hayes RL, Serventi J, Odaimi M, Scheff R, Zaroulis CG, Silverman
P, Grosman I, Lederman G, & Pannullo S. Synergistic efficacy of
sequential fractionated stereotactic radiosurgery plus paclitaxel
(FSRS+T) and adoptive cellular immune therapy (ITX) using
interleukin-2 and activated killer cells (LAK). Proc Amer Assoc
Cancer Res, 2003
Hayes RL, Pannullo S, Wertheim S, Raden M, Grosman I, Silverman
P, & Lederman G. Synergistic efficacy of sequential
fractionated stereotactic radiosurgery (FSR) plus paclitaxel and
adoptive immune therapy (IT) for recurrent glioblastoma multiforme
(RGM). Neuro-Oncol 4:S44, 2002
Hayes RL, Pannullo S, Serventi J, Silverman P, Grosman I, &
Lederman G. Synergistic efficacy of sequential fractionated
stereotactic radiosurgery plus paclitaxel and adoptive cellular
immune therapy. AANS Immunotherapy Task Force, Chicago, IL April
2002
Huang Y, Hayes RL, Wertheim S, Scheff R, & Arbit E.
Treatment of refractory recurrent malignant glioma with adoptive
cellular immunotherapy. American College of Physicians National
Competition, October 1999, Amer Soc of Internal Med, 2000
Huang Y, Hayes RL, Wertheim S, Scheff R, & Arbit E.
Treatment of refractory recurrent malignant glioma with adoptive
cellular immunotherapy. American College of Physicians Local
Competition, November 1999. 2000. Selected for poster presentation
at the Associates Meeting Downstate Competition, April 1, 2000, New
York City, NY [First place winner Research category]
Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α,
β, γ and 13-cis-retinoic acid on the growth and immunomodulation of
human cervical carcinoma cells: Implication for cervical cancer
immunotherapy. Poster presentation, American College of Physicians
National Competition, October 1999. Poster presentation at the ACP
Associates Competition, April 2000, Philadelphia, PA
Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α,
β, γ and 13-cis retinoic acid on the growth and immunomodulation of
human cervical carcinoma cells: Implication for cervical cancer
immunotherapy. Poster presentation, American College of Physicians
Local Competition, Nov 1999.
Huang Y, Hayes RL, Wertheim S, Arbit E, & R Scheff.
Treatment of refractory malignant glioma with adoptive
immunotherapy: A case report. Poster presentation at the
International Conference on Advances in Cancer Immunotherapy,
“Cell-based Therapies” session, March 2, 2000, Princeton, NJ.
Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α,
β, γ and 13-cis-retinoic acid on the growth and immunomodulation of
human cervical carcinoma cells: Implication for cervical cancer
immunotherapy. Poster presentation at the International Conference
on Advances in Cancer Immunotherapy, “Vaccines” session, March 2,
2000, Princeton, NJ.
Huang Y, Hayes R, & Castellanos M. Effects of Interferon-α,
β, γ and 13-cis-retinoic acid on the growth and immunomodulation of
human cervical carcinoma cells: Implication for cervical cancer
immunotherapy. Poster presentation Annual meeting Society of
Gynecologic Oncologists, February 2000, San Diego, CA.
Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5
protein is a potential target for a prophylactic peptide vaccine
against cervical cancer. Poster presentation Annual meeting of the
Society of Gynecologic Oncologists (SGO) February 2000, San Diego,
CA.
Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5
protein is a potential target for a prophylactic peptide vaccine
against cervical cancer. Poster presentation, American College of
Physicians Local Competition, November 1999.
Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5
protein is a potential target for a prophylactic peptide vaccine
against cervical cancer. Poster American College of Physicians
National Competition, October 1999. Selected for presentation at
the ACP Associates Competition, April 2000, Philadelphia, PA
Huang Y, Castellanos M, & Hayes RL. Human papillomavirus E5
protein is a potential target for a prophylactic peptide vaccine
against cervical cancer. Poster presentation, International
Conference on Advances in Cancer Immunotherapy, “Vaccines” session,
March 2, 2000, Princeton NJ.
Castellanos M, Maiman M, & Hayes R. Cervical cancer vaccine:
Generation of tumor specific cytotoxic T lymphocytes by stimulation
with human papilloma virus (HPV) type 18 E6 and E7 peptides.
American College of Physicians National Competition, October 1998.
Selected for poster presentation at the ACP Associates Competition,
April 1999, New Orleans, LA, Amer Soc of Internal Med, 1999
Castellanos M, Maiman M, & Hayes R. Cervical cancer vaccine:
Generation of tumor specific cytotoxic T lymphocytes by stimulation
with human papilloma virus (HPV) type 18 E6 and E7 peptides.
American College of Physicians Local Competition, November 1998.
Selected for poster presentation at the Associates Meeting
Downstate Competition, May 15 1999, New York City, NY [First place
winner Research category]
Castellanos M, Maiman M, & Hayes RL. In vitro sensitization
to human papillomavirus type 18 peptides: Induction of specific
cytotoxic cells. J Immunother 22:456, 1999 (Poster presentation at
the annual meeting of the Society of Biological Therapy, Cambridge
MA October 27-30, 1999).
Castellanos M, Hayes RL, & Maiman M. Cervical cancer
vaccine: Generation of HPV-18 specific cytotoxic T cells (CTL) Soc
Gynecol-Oncol, 1999, Poster presentation Annual meeting Society of
Gynecologic Oncologists (SGO) February 1999, San Francisco, CA.
Castellanos M, Maiman M, & Hayes RL. Cervical cancer
vaccine: Generation of tumor specific cytotoxic T lymphocytes by
stimulation with human papillomavirus (HPV) type 18 E6 and E7
peptides, Amer College of Physicians, Amer Soc of Internal Med,
1999
Hayes RL, Levin M, Musella A, Selker RG, Fried A, Schulder M,
Williams J, Arbit E, & Lederman GS. Virtual trials: An
internet-based brain tumor registry. Proc Amer Assoc Cancer Res
40:39-40, 1999
Castellanos M, & Hayes RL. Identification of peptides
encoded by human papillomavirus (HPV) type 18 E6 and E7 which are
potential cytotoxic T lymphocyte epitopes. Cancer Vaccine Week,
1998, P1-02.
Hayes RL & L Magnotti. Expression of EGF-receptor family
(erbB) homologues in malignant gliomas, Soc Neuro-oncol, 1998
Newcomb EW, Hayes RL, Cohen H & DC Miller. Genetic
alterations in glioblastoma subtypes and patient survival. 12th
International Conference on Brain Tumor Research and Therapy,
1997
Hayes RL, Moore E, Pierz DM & H Makouli. In situ production
of interleukin-12 (IL-12), interleukin-2 (IL-2) and interferon
gamma (IFN-γ) following immunotherapy for recurrent glioblastoma
(GBM). Proc Amer Assoc Cancer Res, 1995
Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore
EJ, Pierz DM, Makouli E & J Ransohoff. Regional immunotherapy
for glioblastoma: Long-term survival, eosinophilia, & in situ
production of cytokines. 9th Interntl Congress Immunol, 1995
Hayes RL, Koslow M, Hiesiger EM, Hochster H, Hymes KB, Chen D,
Moore E, Pierz DM & J Ransohoff. Regional immunotherapy for
malignant brain tumors. Proc Amer Assoc Cancer Res 35:211,
1994.
Hayes RL, Moore EM, Pierz DM, Chen D, DaRosso R, Nirenberg A
& JC Allen. Interleukin-2 (IL-2)-inducible lymphokine-activated
killer (LAK) activity arising in blood following IL-2 plus LAK
therapy into the CSF compartment. Proc Amer Soc Clin Oncol 12:296,
1993.
Hayes RL, Hiesiger EM, Pierz DM & M Koslow. Peripheral blood
(PBL) phenotype changes induced by intracranial Interleukin-2 plus
lymphokine-activated killer cell immunotherapy (IL-2/ LAK) in
patients with malignant gliomas during therapeutic response. Proc
Amer Assoc Cancer Res 34: A2804, 1993.
Hiesiger EM, Hayes RL, Budzilovich GN, Pierz DM & J
Ransohoff. ErbB2 (HER2/neu) and epidermal growth factor receptor
(EGF-R) expression are prognostic factors in glioblastoma (GBM).
Proc Amer Assoc Cancer Res 33:254, 1992
Hayes RL, & EM Hiesiger. Radiolabelling of human glioma
xenografts in athymic nude mice in vivo with epidermal growth
factor (125-I-EGF). Proc Amer Assoc Cancer Res 30:A116, 1989.